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Abstract 
Multiple myeloma is a highly treatable but still incurable malignancy. Many advances have been 
made in the treatment of this disease, particularly thanks to the introduction of the 
immunomodulatory drugs, thalidomide and lenalidomide, and the proteasome inhibitor, bortezomib. 
Different trials have supported the inclusion of consolidation/maintenance therapy as part of a 
sequential approach after induction therapy and transplantation (for eligible patients). This 
therapeutic strategy aims to maintain or even improve response obtained after induction, and 
ultimately to prolong survival. The role of consolidation/maintenance therapy has been assessed in 
patients eligible and ineligible for transplantation, and proved to be a valuable option. The improved 
outcome reported with consolidation/maintenance therapy should, however, be balanced against the 
toxicity profile of such an approach. Prolonged exposure to a drug might in fact increase toxicity, 
and prompt management of adverse events is necessary. 
Introduction 
Multiple myeloma is the second most common hematologic malignancy worldwide. It accounted 
for 20,580 new cancer cases in the United States in 2009, including 11,680 cases in men, 8900 
cases in women, and 10,580 deaths overall. Multiple myeloma is mainly a disease of the elderly; the 
median age at diagnosis is 70 years, with 37% of patients younger than 65 years of age, 26% aged 
65 to 74 years, and 37% older than 75 years.
1
 
For the past 10 years, the median overall survival (OS) for patients with multiple myeloma has 
considerably increased thanks to the use of autologous stem cell transplantation (ASCT) and the 
introduction of the immunomodulatory drugs, thalidomide and lenalidomide, and the proteasome 
inhibitor, bortezomib.
2 and 3
 In particular, in a large analysis of 2981 patients with newly diagnosed 
myeloma, patients diagnosed in the past decade had a 50% improvement in OS compared with 
those who had been diagnosed earlier (44.8 vs. 29.9 months; P < .001). 
2
 Today, new and various 
treatment options including novel agents are now available for transplant-eligible and -ineligible 
patients. 
Consolidation (2-4 cycles of combination therapies) and maintenance (continuous therapy, usually 
with single agents, until disease progression) are commonly used in clinical practice to improve 
outcome after induction therapy.
4
 Although many trials support the use of 
consolidation/maintenance to maintain response achieved after induction therapy and to improve 
patient survival, prolonged exposure to new drugs might increase toxicities. Therefore, appropriate 
management of treatment-related side effects is crucial (Table 1). 
 
Table 1. Toxicities Associated With New Drugs and Related Management 
 
 
 
 
Consolidation/Maintenance Approaches in the Era of Novel Agents 
The high efficacy of thalidomide, lenalidomide, and bortezomib, both upfront and at relapse, has 
provided the basis to evaluate these agents as consolidation/maintenance therapy. The major 
objective is to maintain outcome after induction, prolong duration of response, and ultimately 
prolong survival. The first maintenance therapies date back to 1975 and simply consisted of 
continuing chemotherapy after successful induction treatment with melphalan-prednisone (MP).
5, 
6 and 7
 Response duration was prolonged, but no survival benefit was detected, and this approach was 
no longer used. Single-agent interferon was also assessed as maintenance therapy.
8
 Two 
metaanalyses reported a survival improvement of approximately 6 months with continuous 
interferon administration,
9 and 10
 however, studies led to controversial and conflicting results, and 
this approach was not pursued further because of its toxicity profile. 
To date, different trials assessing the role of consolidation/maintenance therapy with novel agents 
have been performed, and results are promising. 
Young Patients 
For patients younger than 65 years, different effective treatment options including novel agents are 
available. These patients generally receive full-dose induction treatment followed by high-dose 
melphalan (melphalan 200 mg/m
2
) and single or double ASCT. Various studies assessed 
consolidation/maintenance approaches after induction and transplantation in these patients. 
Thalidomide-Based Strategies 
Large phase III studies have evaluated the role of continuous thalidomide as either a single agent or 
in combination with glucocorticoids, and only 3 of 5 trials detected an OS improvement 
(Table 2).
11, 12, 13, 14, 15, 16, 17 and 18
 Initial thalidomide doses ranged from 50 mg to 400 mg in the 5 
studies. In the study conducted by the French group, thalidomide was found to improve the best 
response achieved after randomization (P < .001). The 3-year event-free survival (EFS) was 52% 
for the maintenance arm compared with 37% for no maintenance (P < .009). The respective 4-year 
OS rates were 87% and 75% (P < .04). Drug-related toxicity led to thalidomide discontinuation in 
78 patients (39%), and peripheral neuropathy was the major cause. 
11
 In the Total Therapy 2 study, 
the addition of thalidomide at induction and at maintenance resulted in superior median EFS (6 
years vs. 4 years; P = .001). The 8-year OS estimate was 57% among the 323 patients randomized 
to thalidomide compared with 44% for the 345 in the control arm (P = .09). 
12
 In the Australian 
study, thalidomide was administered as consolidation therapy after ASCT. Thalidomide was given 
for 12 months in addition to continuous prednisolone. This approach improved progression-free 
survival (PFS; at 3 years, 42% vs. 23%; P < .001) and OS (at 3 years, 86% vs. 75%; P = .004) 
compared with prednisolone alone. In particular, the PFS enhancement was independent of response 
achieved after ASCT. Thalidomide was associated with an increased incidence of Grade 3 to 4 
peripheral neuropathy (10% for the thalidomide arm vs. 0% for the control arm; P < .001) but there 
were no differences between arms for thromboembolic events. 
13
 Another study assessed 
thalidomide maintenance given at 50 mg in comparison with interferon alpha maintenance. 
Although thalidomide improved the response before and after ASCT, prolonged EFS and PFS, this 
benefit did not translate into a statistically significant longer survival. Thalidomide maintenance 
was stopped in 33% of patients because of toxicity, with 9% of patients experiencing a Grade 3 
neuropathy. 
14
 In the study conducted by Morgan and colleagues, transplant-eligible patients 
(intensive pathway) received induction with either CTD (cyclophosphamide-thalidomide-
dexamethasone) or CVAD (cyclophosphamide-vincristine-adriamycin-dexamethasone). Patients 
were then randomized for maintenance therapy with thalidomide or placebo. Median PFS was 
longer for patients receiving thalidomide maintenance (30 vs. 23 months; P = .003), with no 
significant difference in OS (3-year OS, 75% vs. 80%; P = .26). Of note, patients with adverse 
interphase fluorescence in situ hybridization did not report either a PFS or OS advantage using 
thalidomide maintenance. Toxicities were inevitably higher for patients receiving thalidomide 
maintenance compared with those who did not, in particular 52% of patients (intensive and 
nonintensive pathways) interrupted maintenance because of treatment-related toxicity. 
15
 
 
 
 
Table 2. Main Maintenance Strategies for Young Patients 
 
 
 
 
 
 Recently, the role of VTD (bortezomib-thalidomide-dexamethasone) vs. TD (thalidomide-
dexamethasone) consolidation after double ASCT has been assessed. After 2 cycles of treatment, 
VTD consolidation increased the complete response (CR)/near CR rate from 63% to 73%, but 3-
year PFS was only marginally improved (60% vs. 48%; P = .042). 
19
 Grade 2 to 3 peripheral 
neuropathy (8.1% vs. 2.4%) was higher in patients receiving VTD than in those treated with TD, 
although no other significant differences between treatment groups in the overall frequency of 
toxicities or the frequency of Grade 3 to 4 adverse events were seen. 
Because of the increased risk of neuropathy and treatment discontinuation with prolonged exposure 
to thalidomide, lenalidomide might be preferred as maintenance therapy. 
Lenalidomide-Based Strategies 
Two randomized phase 3 studies have assessed the role of lenalidomide maintenance compared 
with no maintenance after ASCT.
16 and 17
 
In the CALGB study,
16
 patients received maintenance therapy approximately 100 days after 
transplantation, with no previous consolidation treatment. Median time to progression (TTP) was 
significantly improved in patients receiving maintenance (46 vs. 27 months; P < .001), and an OS 
enhancement was detected as well (3-year OS: 88% vs. 80%). Toxicities were higher with 
lenalidomide, particularly Grade 3 neutropenia (32% vs. 12%; P < .001). Second primary 
malignancies (SPMs) occurred in 8% and 3% of patients in the 2 treatment arms, respectively. 
In the IFM 05-02 study,
17
 patients received 2 months of consolidation therapy within 100 days of 
ASCT (lenalidomide at 25 mg on days 1-21 for two 28-day cycles) and were subsequently 
randomized for maintenance with lenalidomide vs. placebo. Median TTP was longer for the 
lenalidomide group (41 vs. 23 months; P < .001), although there was no difference in terms of OS 
(3-year OS: 80% vs. 88%; P = .29). The rate of Grade 3 or 4 peripheral neuropathy was similar in 
the 2 study groups, and thromboembolic events were more frequent in patients taking lenalidomide 
(6% vs. 2%; P = .01). The incidence of SPMs was 8% in the lenalidomide group and 4% in the 
placebo group. 
Despite the recent concerns about the risk of SPMs with prolonged exposure to lenalidomide, the 
benefits associated with lenalidomide maintenance seem to outweigh the increased risk of SPMs 
and thus this approach remains a valuable option. 
Bortezomib-Based Strategies 
Bortezomib is another attractive option in this setting, although further investigation as maintenance 
therapy is needed. Particularly, lower doses should be used to decrease the risk of peripheral 
neuropathy. 
The HOVON-65/GMMG-HD4 study has recently compared the combination PAD (bortezomib-
doxorubicin-dexamethasone) followed by bortezomib maintenance for 2 years with VAD 
(vincristine-doxorubicin-dexamethasone) followed by thalidomide maintenance for 2 years.
18
 After 
a median follow-up of 41 months, median PFS was 35 months for the PAD group and 28 months 
for the VAD group (P = .002). In patients with renal impairment, the bortezomib-based sequential 
approach improved PFS compared with VAD followed by ASCT and thalidomide maintenance, and 
PFS improved from 13 to 30 months (P = .004). 
In a landmark analysis, superior outcome was reported with bortezomib maintenance, which led to 
longer PFS and OS. There was no difference in SPMs between the 2 treatment groups, thus 
showing that bortezomib does not increase the risk of SPMs.
18
 However, these results should be 
interpreted with caution because no randomization for maintenance was planned, and patients 
assigned to bortezomib maintenance had already received this drug at induction. The better 
tolerability of bortezomib during maintenance and the lower discontinuation rate might explain the 
outcome advantage. 
This study, and the other trials already described, underline the concept that the most appropriate 
therapy for young and transplant-eligible patients should consist of a sequential approach including 
induction with effective drug combinations followed by ASCT and subsequent 
consolidation/maintenance therapy. 
Elderly Patients 
Patients older than 65 years of age are usually not considered eligible for high-dose therapy 
followed by ASCT. For these patients, and for younger patients with comorbidities who would not 
tolerate ASCT, gentler approaches are needed. To date, the combinations VMP (bortezomib-MP) 
and MPT (MP-thalidomide) are considered the standard of care in this setting, and they have 
replaced the former standard MP.
20, 21 and 22
 New drugs are being tested in these patients, and various 
trials have also assessed the role of consolidation/maintenance approaches for elderly patients. 
Thalidomide-Based Strategies 
Thalidomide is a favorable option for maintenance therapy in the elderly because it is administered 
orally. Still, prolonged exposure might cause neurotoxicity. Four studies have evaluated the role of 
continuous thalidomide after MPT induction (Table 3).
15, 23, 24, 25, 26, 27, 28, 29 and 30
 In the Italian study, 
thalidomide was given continuously at a dose of 100 mg/d. Median PFS was 25 months with 
thalidomide maintenance and 15 months with no maintenance (P < .001). Median OS was 47.6 
months vs. 45 months (P = .79), respectively, with 10% and 1% of patients experiencing a 
neurologic toxicity. 
23 and 24
 In the Dutch study, maintenance consisted of 50 mg/d thalidomide. 
25
 
Median EFS was 13 months with MPT vs. 9 months with MP alone (P < .001), and a borderline OS 
advantage favoring MPT followed by thalidomide maintenance was detected (40 vs. 31 months; P = 
.05). However, Grade 3 to 4 neurologic events were quite high in the thalidomide arm (23% vs. 
4%). In the Nordic study, thalidomide was given at 200 mg/d until relapse. 
26
 Thalidomide did not 
significantly improved median PFS (15 vs. 14 months; P = .84), nor a significant OS difference 
between the 2 treatment arms (29 vs. 32 months; P = .16). Grade 3 to 4 peripheral neuropathy was 
detected in 6% of patients who received thalidomide and 1% of those who did not. 
Table 3. Main Maintenance Strategies for Elderly Patients 
 
 
 
Two other studies assessed the effect of thalidomide maintenance after conventional therapy in 
patients not eligible for transplantation.
15 and 28
 PFS was improved in both studies, but no OS 
advantage was seen, probably because of a slight increase in toxicity. In one trial,
28
 patients were 
randomized to thalidomide-interferon or interferon alone maintenance after induction with either 
TD or MP. Thalidomide-interferon maintenance was associated with enhanced median PFS (27.7 
vs. 13.2 months; P = .0068), no survival difference was seen between the 2 maintenance arms 
(52.6 vs. 51.4 months; P = .81). Toxicity was higher with thalidomide-interferon, with a Grade 3 to 
4 neuropathy rate of 7% vs. 0% (P = .0015). In the Medical Research Council Myeloma IX trial, 
15
 
patients ineligible for transplantation (nonintensive pathway) received MP or CTD attenuated and 
were then randomized to receive thalidomide maintenance or no maintenance. Thalidomide 
maintenance improved PFS (11 vs. 9 months; P = .014), and the advantage was particularly evident 
in those who received thalidomide also at induction. No significant OS difference was found (P = 
.995). 
The trials described suggest that the optimal dose of thalidomide in elderly myeloma patients should 
be between 50 and 100 mg/d. To reduce peripheral neuropathy, thalidomide administration should 
not be excessively prolonged.
11
 Thalidomide maintenance should be interrupted when > Grade 1 
peripheral neuropathy occurs so that the patient's quality of life is not negatively affected. Despite 
the PFS advantage reported in these trials, longer follow-up is needed to detect a survival advantage 
with thalidomide maintenance. 
Lenalidomide-Based Strategies 
Similar to thalidomide, lenalidomide is a valuable option for maintenance in the elderly because of 
the oral administration. 
Recently, a phase III study evaluated lenalidomide maintenance after MPR-R (melphalan-
prednisone-lenalidomide) vs. no maintenance (MPR or MP inductions only).
29
 A landmark analysis 
from the start of maintenance was performed and results indicated that lenalidomide maintenance 
after MPR significantly extended median PFS compared with MPR alone (26 vs. 7 months; P < 
.001). Yet, no clear survival advantage was noted with maintenance, and longer follow-up is 
needed. Grade 3 to 4 neutropenia was reported in 7% of patients receiving lenalidomide 
maintenance, and thrombocytopenia in 6%. SPMs were more frequent with MPR-R and MPR (7%) 
compared with MP (3%). However, the PFS benefit associated with lenalidomide maintenance 
outweighs the increased risk of SPMs. 
A phase II study evaluated lenalidomide plus prednisone as consolidation therapy followed by 
lenalidomide alone as maintenance therapy, after PAD induction and reduced-intensity 
transplantation with melphalan 100 mg/m
2
.
30
 This sequential approach resulted in a 2-year PFS of 
69% and a 2-year OS of 86%. Lenalidomide used in combination with prednisone as consolidation 
and used as single agent as maintenance significantly improved response achieved after induction, 
with CR rate increasing from 12% to 40%. Neutropenia remained the major toxicity, with a grade 3 
to 4 event occurring in 16% of patients. 
Data support the use of lenalidomide maintenance therapy in elderly patients with myeloma, despite 
the recent concerns about SPMs. In addition, the lack of neurologic toxicity, makes lenalidomide an 
appropriate option for continuous treatment in this setting. 
Bortezomib-Based Strategies 
The Spanish group assessed the effect of bortezomib maintenance therapy in combination with 
either thalidomide (VT) or prednisone (VP) after induction with VMP or bortezomib-thalidomide-
prednisone.
31
 The dose of bortezomib was 1.3 mg/m
2
 on days 1, 4, 8, and 11 scheduled for 3 years. 
VT showed longer median PFS than VP (39 vs. 32 months), but this difference was not statistically 
significant; similarly, no significant difference in OS was seen between the 2 maintenance 
approaches. Peripheral neuropathy is the major toxicity associated with bortezomib, and was 
reported in 9% of VT patients and 3% of VP patients, although in most of the patients peripheral 
neuropathy had previously developed during induction therapy and worsened with maintenance.
31
 
The role of VT maintenance was also evaluated after the 4-drug induction regimen, VMP plus 
thalidomide (VMPT-VT), in comparison with standard VMP with no maintenance.
32 and 33
 Of note, 
in both treatment arms, the schedule of bortezomib was reduced from twice- to once-weekly 
administration to decrease neurologic toxicity.
34
 During maintenance, bortezomib was administered 
at 1.3 mg/m
2
 every 14 days, thalidomide at 50 mg/d for 2 years or until progression.
32 and 33
 After a 
median duration of maintenance of 14.4 months, 45% of patients achieved a CR. The 1-year 
landmark analysis of PFS in patients completing the 9 induction cycles showed a 2-year PFS of 
63% in the VMPT-VT group and 40% in the VMP group, demonstrating that maintenance with VT 
reduced the risk of disease progression 51% (P = .0003). VT maintenance had also a favorable 
safety profile: 3% of patients experienced Grade 3 to 4 hematological toxicity, 5% Grade 3 to 4 
peripheral neuropathy, and 7% discontinued because of adverse events. 
33
 
Another phase III study assessed bortezomib as single agent given continuously at the dose of 1.6 
mg/m
2
 twice weekly after induction with bortezomib-dexamethasone, VTD, or VMP.
35
 Response 
after induction slightly improved, but toxicities were also higher, with a Grade 3 to 4 peripheral 
neuropathy rate of 5%. 
The data presented show that bortezomib maintenance is feasible and effective in elderly patients, 
and a reduced dose should be adopted to reduce neurologic toxicity. 
Conclusion 
Maintenance therapy is an effective strategy to prolong remission duration and survival in young 
and elderly patients. In the era of novel agents, various maintenance approaches have been tested 
and were associated with a PFS advantage. In young patients, maintenance therapy for 2 years or 
lenalidomide or thalidomide until disease progression improves PFS. These new drugs proved to 
have a positive effect also on OS, although the IFM 05-02 did not detect a survival advantage with 
continuous lenalidomide. As single agents, thalidomide, lenalidomide, or bortezomib maintenance 
proved to be well tolerated, and they can be safely used as part of a sequential approach after 
induction and transplantation. In elderly patients, thalidomide maintenance is a valuable option after 
MPT, yet peripheral neuropathy remains a major drawback. Lenalidomide has the advantage of the 
lack of neurologic toxicity, and it is a valuable option after MPR induction. Bortezomib 
maintenance seems to be most beneficial when used with a reduced schedule to decrease peripheral 
neuropathy. 
Overall, when choosing a consolidation/maintenance approach, physicians should carefully balance 
the potential benefits and risks associated with this strategy. Head-to-head comparisons are 
warranted to better guide physicians in the choice of the best consolidation/maintenance option. 
Future trials will also assess the role of second-generation novel agents, such as carfilzomib, 
pomalidomide, MLN 9708, elotuzumab, and bendamustine as maintenance therapy,
36
 either alone 
or in combination. 
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